Clinical Trials Sponsored by Teva Pharma

Total 9038 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Talampanel for Amyotrophic Lateral Sclerosis (ALS) (ALS)

ALS

United States, Netherlands, Canada, Italy, Spain, Belgium, France, Germany, Hungary, Israel
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Effects of Talampanel on Patients With Advanced Parkinson's Disease

Parkinson Disease | Movement Disorders | Dyskinesias
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety, Tolerability, and Effectiveness of Rasagiline Mesylate in Patients With Parkinson's Disease

Parkinson's Disease
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma

Parkinson's Disease | Malignant Melanoma
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

Schizophrenia

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Schizophrenia

China
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Asthma

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)

Crohn Disease | Colitis, Ulcerative

United States, Bulgaria, Czechia, Hungary, Poland, Spain, Belgium, France, Italy, Japan, Norway, Slovakia, Germany, Canada, Ukraine, United Kingdom, Israel, Serbia
Teva Branded Pharmaceutical Products R&D, Inc.

Active, not recruiting

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (SOLARIS)

Schizophrenia

United States, Bulgaria, China, Romania, Turkey
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Cerebral Palsy, Dyskinetic

United States, Italy, Russian Federation, Spain, Denmark, Israel, Poland, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

Solid Tumors

United States
Vanderbilt University Medical Center
Teva Pharmaceuticals USA

Completed

Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients

Huntington Disease

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease (HART)

Huntington Disease

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel (NEUGR-003)

Chemotherapy-induced Neutropenia

Bulgaria, Romania, Russian Federation, Serbia, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma (CONNECT2)

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia (RISE)

Schizophrenia

United States, Bulgaria
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants (GRANIX)

Healthy Participants

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (CONNECT1)

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO)

Primary Progressive Multiple Sclerosis

United States, Canada, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

Growth Hormone Deficiency

United States, Czechia, Germany, Greece, Hungary, Israel, Serbia, Slovakia, Slovenia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Assessment of LBR-101 In Chronic Migraine

Chronic Migraine

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Relapsing Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

Oral Contraceptive | Follicle Development | Ovarian Follicle | Follicle Count | Follicle Size

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women

Oral Contraceptive | Hemostasis

Germany, Israel, Italy, Spain
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

Exercise-induced Bronchospasm

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

BiPolar

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumors

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Albuterol HFA MDI in Pediatric Participants With Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN) ((PHN))

Postherpetic Neuralgia

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics

Asthma

United States, Thailand
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Czechia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women

Pharmacokinetics

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Persistent Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

Asthma

United States, Canada, Czechia, Hungary, Poland, Russian Federation, South Africa, Thailand, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

Asthma

United States, Germany, Hungary, Poland
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease | COPD
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers

Pharmacokinetics

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

An Efficacy and Safety Study of Fremanezumab in Adults With Migraine (FOCUS)

Migraine Prophylaxis

United States, Belgium, Czechia, Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine

Migraine

United States, Canada, Czechia, Finland, Israel, Japan, Poland, Russian Federation, Spain
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Eosinophilic Asthma

United States, Argentina, Brazil, Canada, France, Mexico, Germany, Greece, Korea, Republic of, Peru, Romania, Russian Federation, Slovakia, Taiwan, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

First Time Use of SD-809 in Huntington Disease (First-HD)

Chorea

United States, Australia, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Asthma

United States
Mt Sinai Hospital, Chicago
Teva Pharmaceuticals USA

Unknown

Naturalistic Adasuve Clinical Trial Study

Agitation

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Australia, Belgium, Chile, Colombia, Denmark, Hungary, Israel, Malaysia, New Zealand, Philippines, Poland, Russian Federation, South Africa, Sweden, Thailand, Argentina, Brazil, Canada, France, Mexico, Netherlands, Ge... and more

Clinical Trials Sponsored by Teva Pharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations